.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Argus Health
Moodys
Citi
UBS
Boehringer Ingelheim
Baxter
Fish and Richardson
McKesson
Teva

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,421,192

« Back to Dashboard

Details for Patent: 9,421,192

Title:Hepatitis C virus inhibitors
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s): Belema; Makonen (North Haven, CT), Nguyen; Van N. (West Haven, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:Nov 06, 2015
Application Number:14/934,538
Claims:1. A compound which is methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-met- hylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2- -yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride.

2. A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-met- hylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2- -yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride.

3. The method of claim 2 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2 S)-1-((2 S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidaz- ol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methyl- propyl)carbamate dihydrochloride.

4. The method of claim 3 wherein at least one of the additional compounds having anti-HCV activity is an interferon or ribavirin.

5. The method of claim 4 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.

6. The method of claim 3 wherein at least one of the additional compounds having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

7. The method of claim 3 wherein at least one of the additional compounds having anti-HCV activity is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.

8. The method of claim 3 wherein at least one of the additional compounds having anti-HCV activity is effective to inhibit the function of a target selected from HCV serine protease and HCV polymerase.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Fish and Richardson
US Army
Covington
Daiichi Sankyo
Teva
Cipla
Julphar
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot